Obinituzumab, a humanized monoclonal against CD20 approved for chronic lymphocytic leukemia, causes profound B-cell depletion; the drug, recently tried in two anti-MAG neuropathy patients resistant or partially responding to rituximab did not show efficacy, in spite of reducing the IgM levels and anti-MAG titers.73 Belimumab against the B-lymphocyte stimulator BLyS, approved for lupus, may be another alternative, although its failure in MS and myasthenia gravis, lowers its priority status.36,54. Here, TNFSF13B is linked to B-cell chronic lymphocytic leukemia.